Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

The investigators propose to determine the engraftment and transplant related morbidity and mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol using immune- suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy in patients with aggressive sickle cell disease who are not candidates for or experienced complications from hydroxyurea therapy.

NCT: NCT01499888

Locations: University of Illinois at Chicago

Link: https://clinicaltrials.gov/ct2/show/NCT01499888?recrs=ad&cond=Sickle+Cell+Anemia&locn=University+of+Chicago&cntry=US&age=0&draw=2&rank=3